{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:01:09Z","timestamp":1788850869097,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.pbb.2021.173316","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T11:06:26Z","timestamp":1640603186000},"page":"173316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Antidepressant-like actions of the mGlu2\/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram"],"prefix":"10.1016","volume":"212","author":[{"given":"Chao","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2021.173316_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2012.09.008","article-title":"Metabotropic glutamate 2\/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice","volume":"65","author":"Ago","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173316_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2021.173316_bb0015","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.1120972","article-title":"Essential role of BDNF in the mesolimbic dopaminergic pathway in social defeat stress","volume":"311","author":"Berton","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pbb.2021.173316_bb0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173316_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/bs.apha.2020.04.001","article-title":"mGlu2\/3 receptor as a novel target for rapid acting antidepressants","volume":"38","author":"Chaki","year":"2020","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173316_bb0035","first-page":"228","article-title":"Rapid and sustained antidepressant action of the mGlu2\/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine","volume":"20","author":"Dong","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pbb.2021.173316_bb0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1461145711001702","article-title":"mTOR activation is required for the antidepressant effects of mGluR2\/3 blockade","volume":"15","author":"Dwyer","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2049-9256-1-15","article-title":"mGluR2\/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure","volume":"1","author":"Dwyer","year":"2013","journal-title":"J. Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2021.173316_bb0060","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/nprot.2011.361","article-title":"A standard protocol for repeated social defeat stress in mice","volume":"6","author":"Golden","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.pbb.2021.173316_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2021.173316_bb0075","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pbb.2021.173316_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2021.173316_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbr.2012.10.023","article-title":"Role of BDNF\/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression","volume":"238","author":"Koike","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2021.173316_bb0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17460441.2020.1822814","article-title":"Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery","volume":"16","author":"Musazzi","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.pbb.2021.173316_bb0100","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1021\/jm0400294","article-title":"Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists","volume":"47","author":"Nakazato","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173316_bb0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1566524015666150330143008","article-title":"Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders","volume":"15","author":"Ohgi","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.pbb.2021.173316_bb0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-010-1978-5","article-title":"On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039","volume":"212","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pbb.2021.173316_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110239","article-title":"The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"109","author":"Pa\u0142ucha-Poniewiera","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0125","doi-asserted-by":"crossref","first-page":"18m12470","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0130","article-title":"Evaluation of the safety, tolerability and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2\/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents","author":"Watanabe","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173316_bb0140","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","author":"Wei","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172854","article-title":"mGlu2\/3 receptor antagonisms: a mechanisms to induce rapid antidepressant effects without ketamine-associated side effects","volume":"190","author":"Witkin","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173316_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173316_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pbb.2017.03.001","article-title":"Preclinical predictors that the orthosteric mGlu2\/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects","volume":"155","author":"Witkin","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173316_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2021.173316_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-acting and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173316_bb0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-006-0390-7","article-title":"An mGluR2\/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats","volume":"186","author":"Yoshimizu","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173316_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pbb.2021.173316_bb0180","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1007\/s00213-015-4062-3","article-title":"Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression","volume":"232","author":"Zhang","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173316_bb0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"Psychiatry Res."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572100215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572100215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:41:53Z","timestamp":1758775313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130572100215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"alternative-id":["S009130572100215X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173316","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant-like actions of the mGlu2\/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173316"}}